📜1,2-二(3,5-二氧代哌嗪-1-基)乙烷置于吡啶体系中,用 水,N,N-二甲基甲酰胺 作为反应溶剂,化学反应 1.5H,反应生成 索布佐生 参考文献:Synthesis And Antitumor Properties Of N1-Acyloxymethyl Derivatives Of Bis(2,6-Dioxopiperazines). 标题:Synthesis And Antitumor Properties Of N1-Acyloxymethyl Derivatives Of Bis(2,6-Dioxopiperazines). 摘要:许多双(2,6-二氧哌嗪)I,Icrf-154的n1-酰氧甲基衍生物vi被制备并测试了其抗肿瘤活性.将i与甲醛反应得到结晶的双(N1-羟甲基)衍生物vii,该衍生物在不同条件下酰化得到双(N1-酰氧甲基)衍生物vi.研究了vi对小鼠p388白血病的抗肿瘤活性.发现几种双(N1-酰氧甲基)化合物如苯乙酰氧甲基vi-6,甲氧羰基氧甲基vi-41,异丁氧羰基氧甲基vi-44和呋喃甲酰甲基vi-38具有强大的抗肿瘤活性.另一方面,酰基中含有氨基或羧酸功能的水溶性酯类显示出较低的活性.这些双(N-1-酰氧甲基)衍生物vi可能通过体内非特异性酯酶水解为母体双(2,6-二氧哌嗪)I来展现其抗肿瘤活性. DOI:10.1248/cpb.37.2976
专利号:US-12391691-B2 优先权日:2018-11-16 标题:Synthesis of key intermediate of KRAS G12C inhibitor compound 发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY 权利人:AMGEN INC 摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as
专利号:US-2025206736-A1 优先权日:2019-11-14 标题 :Synthesis of kras g12c inhibitor compound 发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN 权利人:AMGEN INC 摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
专利号:WO-2017100796-A1 优先权日:2015-12-11 标 题 :Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers 发明人:WONG CHI-HUEY; HSU TSUI-LING; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI 权利人:SINACA ACAD; WONG CHI-HUEY; HSU TSUI-LING 摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.
专利号:US-2017283878-A1 优先权日:2015-12-11 标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers 发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING 权利人:ACADEMIA SINICA 摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.
专利号:US-8734846-B2 优先权日:2008-06-16 标 题 :Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles 发明人:ALI MIR M; HRKACH JEFF; ZALE STEPHEN E; ALVAREZ DE CIENFUEGOS LUIS 权利人:BIND BIOSCIENCES INC 摘要:This application provides nanoparticles and methods of making nanoparticles using pre-functionalized poly(ethylene glycol)(also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. Ring opening polymerization yields the desired poly(ester)-poly (ethylene glycol)-targeting agent polymer that is used to impart targeting capability to therapeutic nanoparticles. This “polymerization fromâ€? approach typically employs precursors of the targeting agent wherein the reactivity of functional groups of the targeting agent is masked using protecting groups. Also described is a “coupling toâ€? that utilized the poly(ethylene glycol)-targeting agent conjugate where the targeting agent remains in its native un-protected form. This method uses “orthogonalâ€? chemistry that exhibit no cross reactivity towards functional groups typically found within targeting agents of interest.
专利号:US-2013035307-A1 优先权日:2010-01-26 标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers 发明人:PRESTWICH GLENN D; KENNEDY THOMAS P 权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P 摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.
1: Reimerová P, Jirkovská A, Piskáčková HB, Karabanovich G, Roh J, Šimůnek T, Štěrbová-Kovaříková P. UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study. Sci Rep. 2019 Mar 14;9(1):4524. doi: 10.1038/s41598-019-40928-5. 2: Inoue Y, Tsukasaki K, Nagai K, Soda H, Tomonaga M. Durable remission by sobuzoxane in an HIV-seronegative patient with human herpesvirus 8-negative primary effusion lymphoma. Int J Hematol. 2004 Apr;79(3):271-5. doi: 10.1532/ijh97.03107. 61(5):739-49. doi: 10.1007/s00280-007-0528-2. Epub 2007 Jun 27. 55(7):815-9. Japanese. 37(2):347-50. Japanese. 17(1):69-71. Chinese. 34(6):885-9. Japanese. 21(7):1089-97. Japanese. 19(3):339-47. Japanese. 10(3):209-14. doi: 10.1016/0890-6238(96)00023-8. 20(1):42-9. Japanese. 37(5):2309-15. doi: 10.1007/s11033-009-9730-0. Epub 2009 Aug 21. 21(7):1009-15. Japanese. 18(10):1709-12. Japanese. 18(14):2447-52. Japanese. 18(14):2441-6. Japanese. 51(12):3291-300. Japanese. 1400(1-3):155-71. doi: 10.1016/s0167-4781(98)00133-x. 10(7):564-70. doi: 10.2174/187152010793498654. 18(12):2179-82. Japanese.
合成参考文献
摘要:Sakai C, Murotani N. [Adult T-cell leukemia/lymphoma in a patient on hemodialysis-resistance to CHOP, but unexpected effect and remission achieved by sobuzoxane alone]. Gan To Kagaku Ryoho. 2010 Feb;37(2):347–50.